Adaptive Biotechnologies Corporation Common Stock
ADPTAdaptive Biotechnologies Corporation focuses on immune-driven medicine and develops immune system-based diagnostics and therapeutics. It leverages its proprietary immune sequencing platform to understand and interpret the adaptive immune system, primarily through analyzing T-cell and B-cell receptors to improve disease detection and treatment. The company collaborates with various research and pharmaceutical organizations to advance immunotherapy and immune-based diagnostics.
Company News
Bank of America expects Pfizer's 2026 financial outlook to remain flat, with challenges from ongoing patent exclusivity losses and limited pipeline catalysts. The company is focusing on areas like obesity treatments, antibody-drug conjugates, and pneumococcal franchise development.
Adaptive Biotechnologies presented 90 abstracts at the ASH Annual Meeting, highlighting its clonoSEQ® test's effectiveness in guiding treatment interventions across multiple blood cancer types, demonstrating precision in measurable residual disease (MRD) monitoring.
Adaptive Biotechnologies' stock dropped after Natera acquired Foresight Diagnostics for $275 million upfront, raising competitive concerns in the blood-cancer minimal residual disease (MRD) market.
Adaptive Biotechnologies reported strong Q2 2025 results with 36% revenue growth, primarily driven by minimal residual disease (MRD) business. The company beat analyst expectations and raised its MRD revenue guidance for 2025.
The U.S. minimal residual disease testing market is projected to reach $2020 million by 2033, growing at a 9.38% CAGR, driven by rising cancer rates and advancements in precision medicine technologies like NGS and flow cytometry.
